A detailed history of Thrivent Financial For Lutherans transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 27,605 shares of ZNTL stock, worth $82,815. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,605
Previous 27,605 -0.0%
Holding current value
$82,815
Previous $112,000 9.82%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.09 - $16.13 $4,830 - $19,049
-1,181 Reduced 4.1%
27,605 $112,000
Q4 2023

Feb 14, 2024

SELL
$9.84 - $20.13 $13,835 - $28,302
-1,406 Reduced 4.66%
28,786 $436,000
Q2 2023

Aug 14, 2023

SELL
$17.41 - $30.05 $25,801 - $44,534
-1,482 Reduced 4.68%
30,192 $852,000
Q2 2022

Aug 16, 2022

BUY
$17.91 - $52.25 $567,281 - $1.65 Million
31,674 New
31,674 $890,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.